Last week, Quartz Bio said that it had been selected to provide bioinformatics support for biomarker projects conducted by the Debiopharm group, a Swiss-based biopharmaceutical company.

Under the terms of the one-year agreement, the Merck Serono spinoff (BI 9/7/2012) will provide computational analyses for Debiopharm projects in areas such as preclinical next-generation sequencing and clinical biomarker data analyses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: method to detect single-nucleotide and copy-number alterations in single cells from archival tissue, and more.

China has announced new rules governing the use of stem cell treatments, Nature News reports.

Wired's Sarah Zhang expresses frustration as a microbiome study of homes uncovers expected bacteria.

A database containing genome sequences from strains of foodborne pathogens may enable regulators and companies to quickly identify outbreak sources, Reuters reports.